Myozyme 50 mg, powder for concentrate for solution for infusion.

  • Name:

    Myozyme 50 mg, powder for concentrate for solution for infusion.

  • Company:
    info
  • Active Ingredients:

    Alglucosidase alfa

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 03/12/19

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 3/12/2019

Click on this link to Download PDF directly

Sanofi Genzyme

Sanofi Genzyme logo_1556886599

Company Products

Medicine NameActive Ingredients
Medicine Name Aldurazyme 100 U/ml concentrate for solution for infusion Active Ingredients Laronidase
Medicine Name AUBAGIO 14 mg film-coated tablets Active Ingredients Teriflunomide
Medicine Name Caprelsa 100mg and 300mg film coated tablets Active Ingredients Vandetanib
Medicine Name Cerdelga 84 mg capsules, hard Active Ingredients Eliglustat tartrate
Medicine Name Cerezyme 400 U Powder for concentrate for solution for infusion Active Ingredients Imiglucerase
Medicine Name Cholestagel 625mg film coated Tablets Active Ingredients Colesevelam hydrochloride
Medicine Name Evoltra 1 mg/ml concentrate for solution for infusion Active Ingredients Clofarabine
Medicine Name Fabrazyme 35 mg, powder for concentrate for solution for infusion Active Ingredients Agalsidase beta
Medicine Name Fabrazyme 5 mg, powder for concentrate for solution for infusion Active Ingredients Agalsidase beta
Medicine Name Fasturtec Active Ingredients Rasburicase
Medicine Name Fludara 50 mg powder for solution for injection or infusion Active Ingredients Fludarabine Phosphate
Medicine Name Fludara oral 10 mg film-coated tablets Active Ingredients Fludarabine Phosphate
Medicine Name LEMTRADA 12 mg concentrate for solution for infusion Active Ingredients Alemtuzumab
Medicine Name Mozobil 20 mg ml solution for injection Active Ingredients Plerixafor
Medicine Name Myozyme 50 mg, powder for concentrate for solution for infusion. Active Ingredients Alglucosidase alfa
Medicine Name Thymoglobuline 25 mg powder for solution for infusion Active Ingredients Rabbit Anti-Human Thymocyte Immunoglobulin
Medicine Name Thyrogen 0.9 mg powder for solution for injection Active Ingredients Thyrotropin alfa
1 - 0 of 17 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 3 December 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 3 December 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 28 November 2019 Ed-HCP

Reasons for updating

  • Replace document

Updated on 11 October 2019 Ed-HCP

Reasons for updating

  • Add New Doc

Updated on 16 September 2019 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 18 January 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 7 January 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder

Updated on 7 January 2019 SmPC

Reasons for updating

  • Change to section 4.9 - Overdose
  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.9     Overdose

 

There is no experience with overdose of alglucosidase alfa. In clinical studies doses up to 40 mg/kg body weight were used.

 

7.       MARKETING AUTHORISATION HOLDER

 

Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands

Updated on 18 May 2018 PIL

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 19 October 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 19 October 2017 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 15 September 2017 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 29 August 2017 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 23 August 2017 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 Section 4.8:

Correction to the HPRA fax number.

Updated on 23 August 2017 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 23 August 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 18 July 2017 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update of section 4.8 of the SmPC to add the adverse reactions infusion site swelling, infusion site induration and infusion site extravasation with a frequency not known. The Package leaflet is updated accordingly

Updated on 17 July 2017 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 17 February 2015 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 17 February 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 4.8: The HPRA adverse event reporting address has been updated. The Maltese adverse event reporting address has been included.

Updated on 23 September 2014 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.1: deletion of the sentence: “In patients with late-onset Pompe disease, the evidence of efficacy is limited (see section 5.1)”;

Section 4.4: inclusion of Immunomodulation warning as below;

Immunomodulation

Patients with Pompe disease are at risk of respiratory infections due to the progressive effects of the disease on the respiratory muscles. Immunosuppressive agents have been administered in experimental settings in a small number of patients, in an attempt to reduce or prevent the development of antibodies to alglucosidase alfa. Fatal and life-threatening respiratory infections have been observed in some of these patients. Therefore, treating patients with Pompe disease with immunosuppressive agents may further increase the risk of developing severe respiratory infections and vigilance is recommended.

Section 4.8: Inclusion of reporting of adverse reactions advisory. Additionally, the following has been added;

Recurrent reactions consisting of flu-like illness or a combination of events such as fever, chills, myalgia, arthralgia, pain, or fatigue occurring post-infusion and lasting usually for a few days, have been observed in some patients treated with alglucosidase alfa. The majority of patients were successfully re-challenged with alglucosidase alfa using lower doses and/or pretreatment with anti-inflammatory drugs and/or corticosteroids and have continued to receive treatment under close clinical supervision.

Section 5.1: Inclusion of clinical trial information as below:

Late-onset Pompe disease; other clinical trials and analyses

Three independent, open-label, single arm, investigator-initiated studies with Myozyme were conducted:

•             One study in Italy enrolled 74 late-onset patients with up to 48 months follow up.

•             One study in Germany enrolled 38 late-onset patients with 36 months follow up.

•             One study in the Netherlands enrolled 69 late-onset patients with a median follow-up of 23 months.

These three studies with Myozyme (with a follow up of at least 3 years in two studies and a median of 23 months in the other study) suggested stabilisation or improvement of motor function and stabilisation of pulmonary function.

In the above described study in 69 late-onset patients in the Netherlands, Myozyme showed an improvement in muscle strength. However, muscle function only improved in wheelchair independent patients and in those with less pronounced muscle weakness.

In two additional open-label clinical trials with Myozyme with a follow-up of 24 months, ten patients with severe late-onset Pompe disease (moderate to severe motor impairment and assisted ventilation) showed a variable response on measures of motor and respiratory functions, mostly in the form of a modest improvement (AGLU03105, AGLU04107).

In addition: several minor changes were also made to the SPC to bring it in line with the current QRD template.

Updated on 23 September 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Changes to therapeutic indications

Updated on 22 May 2013 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Shelf life extended from 2 years to 3 years

Updated on 30 August 2012 PIL

Reasons for updating

  • Removal/change of distributor

Updated on 15 December 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 15 December 2011 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4 Inclusion of paragraph on necrotic syndrome

Section 4.8: update of AEs

Section 10: Date revised

Updated on 25 February 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to further information section
  • Change to date of revision

Updated on 25 February 2011 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
  • Change to section 4.2 - Posology and method of administration

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to sections:

 

2. Qualitative and Quantitative Composition

 

Removal of the sentence “Alglucosidase alfa is a recombinant form of”

 

4.1 Therapeutic indications

 

Addition of the sentence Myozyme is indicated in adults and paediatric patients of all ages”.

 

4.2 Posology and method of administration

 

Method of Administration section has moved to after the Renal & Hepatic impairment section

 

Under “Paediatric and elderly population” – “administered to children, adolescents” has been changed to “administered to pediatric patients of all ages

 

Under “Renal and hepatic impairment” – “hepatic insufficiency” has been changed to “hepatic impairment

 

4.4 Special warnings and precautions for use.

 

The headers “Hypersensitivity/Anaphylactic reactions”,

 “Infusion Associated Reactions”, “Immuogenicity”.

 “Transient Nephrotic syndrome” and “Immune complex-mediated reactions” have been added.

 

At the end of the first paragraph under the Header “Infusion Associated Reactions” “reported to Genzyme” had been changed to “reported to the marketing authorisation holder

 

4.6 Fertility, pregnancy and lactation

 

The section Fertility has been added

 

4.7 Effects on ability to drive and use machines

 

Addition of last sentence

 

4.8 Undesirable effects

 

In the first paragraph the sentence “Most adverse events reported in these 39 patients were due to manifestations of Pompe disease and not related to the administration of Myozyme” has been deleted

 

Changes made in the section “Table – 1” changes also made in the actual table.  Addition of Superscript 4 at the bottom of the table and removal of the first 2 paragraphs after the table. 

Second paragraph from the end, of this section has been removed.

 

4.9 Overdose

 

Re-wording of this sentence

 

5.1 Pharmacodynamics properties

 

“Alglucosidase alfa” has been removed from the end of the first paragraph

 

6.1  List of Excipients

 

Change to - Sodium dihydrogen phosphate monohydrate and Disodium phosphate heptahydrate

 

6.3 Shelf Life

 

Changed to 2 years from 24 months

 

6.4  Special precautions for storage

 

For storage conditions of the diluted medicinal product, see section 6.3 – has been added.

 

6.5 Nature and contents of container

 

The word Clear has been removed from the bracketed section (Clear Type-1 glass)

 

6.6 Special precautions for disposal and other handling

 

First sentence has been reworded

At the end of paragraph 3 the section “As Myozyme does not contain a preservative” has been removed.

Under the Dilution section the paragraph has been reworded

 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

Date of latest renewal has been added

 

10 Date of Revision of the Text

 

Change of date.

Updated on 15 September 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 15 September 2010 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to sections:

 

2. Qualitative and Quantitative Composition

 

Addition of the sentence “Alglucosidase alfa is a recombinant form of human acid α-glucosidase and is produced in Chinese hamster ovary cells by recombinant DNA technology.”

 

 

4.2 Posology and method of administration

 

Addition of header “Posology” and deletion of “as an intravenous infusion”

Addition of header and infusion instructions “Method of Administration”  “Myozyme should be administered as an intravenous infusion.”  And addition of paragraph “Patient response to treatment should be routinely evaluated based on a comprehensive evaluation of all clinical manifestations of the disease.”

Addition of header “Paediatric and elderly population”

Addition of header “Renal and hepatic impairment” plus addition of paragraph – “For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6”  Deletion of “Patient response to treatment should be routinely evaluated based on a comprehensive evaluation of all clinical manifestations of the disease”

 

4.4 Special warnings and precautions for use.

 

Addition of last paragraph – “Severe cutaneous reactions, possibly immune-mediated, have been reported with alglucosidase alfa, including ulcerative and necrotizing skin lesions (see section 4.8). Patients should be monitored for signs and symptoms of systemic immune complex-mediated reactions involving skin and other organs while receiving alglucosidase alfa. If immune-mediated reactions occur, discontinuation of the administration of alglucosidase alfa should be considered and appropriate medical treatment initiated. The risks and benefits of re-administering alglucosidase alfa following an immune-mediated reaction should be considered. Some patients have been successfully rechallenged and continued to receive alglucosidase alfa under close clinical supervision.”

 

4.5 Interaction with other medicinal products and other forms of interaction

 

Re-wording of paragraph.

 

4.6 Fertility, pregnancy and lactation

 

Addition of Fertility in the header and change of “Lactation” to “Breast-feeding”

 

4.8 Undesirable effects

 

Addition of “conjunctivitis, abdominal pain, arthralgia, apnea and respiratory arrest” to “Post-marketing data: unknown frequency (cannot be estimated from the available data)” Also addition of paragraph below “Severe cutaneous reactions, possibly immune-mediated, have been reported with alglucosidase alfa including ulcerative and necrotizing skin lesions (see section 4.4).

 

5.1 Pharmacodynamic properties

 

Deletion of “Alglucosidase alfa is a recombinant form of human acid α-glucosidase and is produced by recombinant DNA technology using Chinese Hamester Ovary (CHO) cell culture”

 

10 Date of Revision of the Text

 

Change of date.

Updated on 23 June 2010 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 22 June 2010 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided